PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit attended the 5th RAS Initiative Symposium, hearing about ...
Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS, and HRAS. RAS-family mutations are associated with numerous types of cancer.
*仅供医学专业人士阅读参考作为最强的促癌基因，KRAS激活突变自1982年发现以来，已经过去了40多年。然而靶向KRAS突变的第一款药物，直到三年前才获批上市。不过，药物虽然已经出现，但是治疗效果却不尽如人意。在接受治疗的患者中，对药物有反应的患者不 ...
Human cell transformation systems revealed that RAL-GEF signaling is particularly required for oncogenic RAS function in human cancer. Murine Kras-driven lung cancer models have confirmed the key ...
Roche/Chugai’s pan-RAS inhibitor LUNA18 has already completed a dose-ranging study, while Quanta’s multi-KRAS inhibitor QTX3034 is in preclinical development. Stephen Fawell, AZ’s head of ...
Protects the use of onvansertib in combination with standard of care in the KRAS mutated mCRC setting through 2043 ... the first-line setting in combination with standard of care for RAS-mutated mCRC ...
Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025 Strong execution across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback